Auranofin
1 NDC across 1 manufacturer|0 Generic,1 Brand
Auranofin is used to treat psoriatic arthritis, rheumatoid arthritis and pemphigus, per the National Library of Medicine's MED-RT classification.
▸ More about this market▾ Less
The brand product was first FDA-approved on May 24, 1985. In 2024, Medicare Part D spent $922K on Auranofin across 635 claims for 88 beneficiaries.
Auranofin is available as 1 NDC from 1 manufacturer (0 generic, 1 brand), with NADAC prices from $24.85 to $24.85 per EA. Every pack size and labeler in this drug market is compared side-by-side below.
Total NDCs
1
0G / 1B
Manufacturers
1
competing in market
Price Spread
$24.85 – $24.85
per EA
7d Activity
avg +0.0% WoW · of 1 NDCs
Market Price Trend
Monthly average NADAC per unit, split by generic and brand.
Manufacturer Breakdown
1 manufacturer producing AURANOFIN
| Drug ↕ | Price | 7d Change ↕ |
|---|---|---|
RIDAURA 3 MG CAPSULE | $24.8454 per EA | — |
Frequently Asked Questions
What is Auranofin used to treat?
Auranofin is used to treat psoriatic arthritis, rheumatoid arthritis and pemphigus, per the National Library of Medicine's MED-RT classification.
How much does Medicare spend on Auranofin?
In 2024, Medicare Part D spent $922K on Auranofin across 635 claims for 88 beneficiaries.
How many Auranofin products are on the market?
The Auranofin drug market contains 1 NDC from 1 manufacturer — 0 generic and 1 brand product.
What is the price range for Auranofin?
NADAC reference prices for Auranofin range from $24.8454 to $24.8454 per EA.
Which manufacturers make Auranofin?
1 manufacturer lists Auranofin in NADAC. Ranked by number of NDCs, the largest are Sebela Pharmaceuticals Inc. (1).